All In Biotech

NDA 018861 · Fougera

Betamethasone Valerate

Betamethasone Valerate · Topical

Last checked: Nov 20, 2026Latest source record: Dec 4, 1997 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

Aug 31, 1983

Approved uses

1

Original approval plus efficacy supplements

Registered trials

34

9 Phase 3, 2 recruiting

FAERS reports

4,595

4,066 serious, 240 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 28, 2026.

INDICATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 31, 1983 Original approval
1 products under this application
  • BETAMETHASONE VALERATE · BETAMETHASONE VALERATE EQ 0.1% BASE · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone Valerate" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,081
  • macular degeneration644
  • pain611
  • off label use501
  • pyrexia428
  • malaise424
  • nausea422
  • headache416
  • weight decreased416
  • pruritus353
  • rash338
  • abdominal pain308

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200413
200513
200615
200717
200821
200925
201039
201156
201252
201385
2014127
2015179
2016213
2017189
2018209
2019345
2020350
2021570
2022479
2023499
2024427
2025388
2026284

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Betamethasone Valerate (Betamethasone Valerate)

2024 spending

$8.9M

Beneficiaries

154,260

279,579 claims

Per beneficiary

$58

$0.67 per unit

View as table
YearSpending
2020$10,901,023
2021$10,638,627
2022$10,499,064
2023$9,949,201
2024$8,945,616

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 187 on PubMed

Sponsor: Fougera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.